ArticleJournal of medical biochemistry2021
High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase.
Article in Journal of medical biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Serum High Mobility Group Box Protein-1 Levels in Schizophrenia During Acute Psychotic Episodes and Remission.Noro psikiyatri arsivi · 2026Article
- Effect of olanzapine on changes in serum complement factors levels in patients with first-episode schizophrenia.BMC psychiatry · 2025Article
- Serum HMGB1 as a diagnostic biomarker and mediator of childhood trauma in adolescent depression.Frontiers in psychiatry · 2025Article
- High Mobility Group Box 1 Levels as an Inflammatory Mediator in Bipolar Mania.Noro psikiyatri arsivi · 2024Article
- Serum HMGB1 and Beclin 1 Levels in Patients with a Diagnosis of Schizophrenia.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024Article
- Advanced Biomarkers of Hepatotoxicity in Psychiatry: A Narrative Review and Recommendations for New Psychoactive Substances.International journal of molecular sciences · 2023Review
- Systematic Review and Meta-Analysis of Damage Associated Molecular Patterns HMGB1 and S100B in Schizophrenia.Psychiatry investigation · 2022Article
- Alterations in innate immune defense distinguish first-episode schizophrenia patients from healthy controls.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.